How a specific drug can reduce inflammation in muscular dystrophy
Mechanisms of mineralocorticoid receptor antagonism on inflammation in muscular dystrophy
This study is looking at how certain medications can help reduce inflammation and improve muscle strength in adults with Duchenne Muscular Dystrophy, especially when used with gene therapy, to make treatments more effective.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-11010812 on NIH RePORTER |
What this research studies
This research investigates the effects of mineralocorticoid receptor antagonists on inflammation in patients with Duchenne Muscular Dystrophy (DMD). It aims to explore how these drugs can stabilize muscle membranes, improve muscle strength, and reduce fibrosis while working alongside gene therapy approaches. The study will assess the potential of these antagonists to mitigate chronic inflammation that arises from muscle damage and the immune response to gene therapy. By focusing on adult patients, the research seeks to provide insights into improving treatment outcomes for those affected by DMD.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older diagnosed with Duchenne Muscular Dystrophy.
Not a fit: Patients with other forms of muscular dystrophy or those under 21 years old may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options that reduce inflammation and enhance muscle function in patients with muscular dystrophy.
How similar studies have performed: Previous research has shown that mineralocorticoid receptor antagonists can provide clinical benefits in related conditions, suggesting potential for success in this novel application.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Rafael-Fortney, Jill a — Ohio State University
- Study coordinator: Rafael-Fortney, Jill a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.